Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 995,830 | 994,227 | 1,004,852 | 1,032,135 | 984,168 |
| Cost of Goods | 701,166 | 684,543 | 666,060 | 675,068 | 666,436 |
| Gross Profit | 294,664 | 309,684 | 338,792 | 357,067 | 317,732 |
| Operating Expenses | 174,933 | 593,667 | 205,053 | 257,001 | 243,499 |
| Operating Income | 119,897 | -283,440 | 133,799 | 100,134 | 74,669 |
| Interest Expense | 26,742 | 23,775 | 25,403 | 29,967 | 27,884 |
| Other Income | -123,097 | 13,116 | -21,196 | 1,251 | -10,807 |
| Pre-tax Income | -29,942 | -294,099 | 87,200 | 71,418 | 35,978 |
| Income Tax | -15,140 | -17,809 | 31,644 | 18,725 | 10,100 |
| Net Income Continuous | -14,802 | -276,290 | 55,556 | 52,693 | 25,878 |
| Minority Interests | 41 | 265 | 1,134 | 367 | 409 |
| Net Income | $-14,843 | $-276,555 | $54,422 | $52,326 | $25,469 |
| EPS Basic Total Ops | -0.30 | -5.58 | 1.11 | 1.06 | 0.50 |
| EPS Basic Continuous Ops | -0.30 | -5.58 | 1.13 | 1.07 | 0.51 |
| EPS Diluted Total Ops | -0.30 | -5.57 | 1.10 | 1.06 | 0.50 |
| EPS Diluted Continuous Ops | -0.30 | -5.57 | 1.12 | 1.07 | 0.51 |
| EPS Diluted Before Non-Recurring Items | N/A | 2.39 | 2.43 | 3.12 | 2.34 |
| EBITDA(a) | $187,048 | $-40,163 | $218,963 | $219,641 | $195,033 |